---
firstreceived_date: September 22, 2014
is_fda_regulated: 'Yes'
reference: []
overall_contact_backup: {}
completion_date:
  attributes:
    type: Actual
  value: October 2015
responsible_party: {}
firstreceived_results_date: 
is_section_801: 'Yes'
detailed_description: {}
link: []
has_expanded_access: 'No'
id: NCT02251600
intervention:
- intervention_name: Deflazacort
  other_name: []
  description: Oral deflazacort administered once daily at 0.9 mg/kg for eight days
  arm_group_label:
  - Deflazacort
  intervention_type: Drug
source: Marathon Pharmaceuticals, LLC
eligibility:
  gender: Male
  maximum_age: 16 Years
  sampling_method: 
  minimum_age: 4 Years
  study_pop: {}
  criteria:
    textblock: |-
      Inclusion Criteria:

                -  In the opinion of the investigator, the subject is capable of understanding and
                   complying with protocol requirements.

                -  The subject or, when applicable, the subject's legally acceptable representative
                   signs and dates a written, informed consent form and any required privacy
                   authorization prior to the initiation of any study procedures.

                -  If above the age of 7, the subject signs and dates a written, informed assent form
                   (IAF) and any required privacy authorization prior to the initiation of any study
                   procedures.

                -  The subject must have confirmed diagnosis of Duchenne Muscular Dystrophy defined as
                   muscle biopsy and dystrophin analyses consistent with DMD or DNA mutation and
                   analysis by PCR or Southern blot techniques to detect gene deletions as well as:

                     1. onset of weakness before 5 years of age;

                     2. proximal muscle weakness;

                     3. increased serum creatine kinase more than 10 times the upper limit of normal
                        (ULN);

                -  The subject is male and aged 4 to 16 years, inclusive.

                -  The subject weighs at least 13 kg and has a Body Mass Index (BMI) of ≤ 40.

                -  Willingness and ability to comply with scheduled visits, oral drug administration,
                   and study procedures including blood sample draws (total blood volume collected not
                   to exceed 50 mL for the study duration or 25 mL on any single study day [≤ 3 mL/kg])

                -  The subject has a life expectancy of >1 year.

                -  Up to date on all childhood vaccinations, specifically varicella vaccine (chicken
                   pox).

                -  Baseline health is judged to be stable based on medical history, physical
                   examination, laboratory profiles, vital signs, or ECGs at screening, as deemed by the
                   Investigator.

                -  Continuous non smoker who has not used nicotine containing products for at least 3
                   months prior to the first dose.

                -  The subject is able to take tablets.

              Exclusion Criteria:

                -  The subject has received any investigational compound and/or has participated in
                   another clinical study within 90 days prior to study treatment with the exception of
                   observational cohort studies or non-interventional studies.

                -  The subject has received deflazacort within 30 days or previous discontinued
                   deflazacort due to an intolerable reaction.

                -  The subject is an immediate family member, study site employee, or is in a dependent
                   relationship with a study site employee who is involved in the conduct of this study
                   (e.g. spouse, parent, child, sibling) or may consent under duress.

                -  Any significant finding on the Columbia suicide severity rating scale (C SSRS) for
                   subjects (ages 12-16, inclusive), in the opinion of the PI, warrants exclusion from
                   this study.

                -  The subject has, in the judgment of the investigator, clinically significant abnormal
                   clinical chemistry laboratory parameters that may affect safety at Screening.

                -  The subject has, in the judgment of the investigator, a history or current medical
                   condition that could affect safety including, but not limited to:

                     1. Major renal or hepatic impairment

                     2. Immunosuppression or other contraindications for corticosteroid treatment

                     3. History of chronic systemic fungal or viral infections

                     4. Diabetes mellitus

                     5. Idiopathic hypocalcuria

                     6. Symptomatic cardiomyopathy at screening

                -  The subject has a history of hypersensitivity or allergic reaction to steroids or
                   their formulations including, but not limited to lactose, sucrose, etc.

                -  Inability to take tablets as assessed by site investigator.

                -  Unable to refrain from or anticipates the use of:

                     -  Any medications at least 4 hours before and after dosing on PK Days 1 and 8.

                     -  Any vitamins, vitamins with minerals, and/or meal supplementation (e.g., Ensure,
                        Boost, etc.) at least 4 hours before and after dosing on PK Days 1 and 8.

                     -  Any drug, including prescription and non prescription medications, and herbal
                        remedies known to be significant inhibitors of CYP 3A4 enzymes and/or P gp for
                        14 days prior to the first dose of study drug and throughout the study.
                        Appropriate sources will be consulted by the PI or designee to confirm lack of
                        pharmacokinetic/pharmacodynamic interaction with study drug. Acetaminophen may
                        be permitted during the study (doses to be based upon appropriate age/weight
                        ranges.

                     -  Any drugs known to be significant inducers of CYP 3A4 enzymes and/or P gp for 28
                        days prior to the first dose of study drug and throughout the study. Appropriate
                        sources will be consulted by the PI or designee to confirm lack of
                        PK/pharmacodynamics interaction with study drug.

                -  Subject is mentally or legally incapacitated or has significant emotional problems at
                   the time of screening visit or expected during the conduct of the study.

                -  History of any illness that, in the opinion of the PI, might confound the results of
                   the study or poses an additional risk to the subject by their participation in the
                   study.

                -  Positive urine drug or alcohol results at screening or check in.

                -  Positive urine cotinine at screening.

                -  Positive results at screening for HIV, HBsAg, or HCV.

                -  Hemoglobin level below the lower limit of normal at screening.

                -  Donation of blood or significant blood loss within 56 days prior to the first dose of
                   study drug.
  healthy_volunteers: 'No'
removed_countries: {}
other_outcome: []
primary_completion_date:
  attributes:
    type: Actual
  value: October 2015
last_injected: '2015-10-21T22:50:44.534Z'
intervention_browse:
  mesh_term:
  - Deflazacort
target_duration: 
number_of_arms: '1'
start_date: December 2014
why_stopped: 
id_info:
  org_study_id: MP-104-CL-005
  secondary_id: []
  nct_alias: []
  nct_id: NCT02251600
acronym: 
arm_group:
- description: 
  arm_group_label: Deflazacort
  arm_group_type: Experimental
sponsors:
  collaborator: []
  lead_sponsor:
    agency: Marathon Pharmaceuticals, LLC
    agency_class: Industry
secondary_outcome:
- safety_issue: 'Yes'
  time_frame: Day 1-8
  description: 
  measure: Number of participants with adverse events as a measure of safety and tolerability
study_type: Interventional
biospec_retention: 
overall_status: Completed
primary_outcome:
- safety_issue: 'No'
  time_frame: Day 1, Day 8
  description: 
  measure: The area under the plasma concentration time curve, from time 0 to the
    last measurable concentration non-zero, for single-state pharmacokinetics on Day
    1 of deflazacort and 21-desacetyl-DFZ, the active metabolite
- safety_issue: 'No'
  time_frame: Day 8
  description: 
  measure: The area under the plasma concentration versus time curve over the final
    dosing interval for steady state pharmacokinetics on Day 8 of deflazacort and
    21-desacetyl-DFZ, the active metabolite
overall_official:
- first_name: 
  last_name: Katherine Smith, MD
  middle_name: 
  affiliation: Drug Safety Solutions/Celerion
  degrees: 
  role: Study Chair
phase: Phase 1
location_countries:
  country:
  - United States
condition:
- Duchenne Muscular Dystrophy
clinical_results: {}
study_design: 'Endpoint Classification: Pharmacokinetics Study, Intervention Model:
  Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science'
keyword:
- Pediatric
- Adolescent
- Deflazacort
results_reference: []
oversight_info:
  has_dmc: 'No'
  authority:
  - 'United States: Food and Drug Administration'
number_of_groups: 
location:
- status: 
  contact_backup: {}
  facility:
    name: UCLA
    address:
      city: Los Angeles
      state: California
      zip: 
      country: United States
  investigator: []
  contact: {}
  geodata:
    latitude: 34.052
    formatted: Los Angeles, CA, USA
    longitude: -118.244
    original: Los Angeles, California
- status: 
  contact_backup: {}
  facility:
    name: Lurie Children's Hospital
    address:
      city: Chicago
      state: Illinois
      zip: 
      country: United States
  investigator: []
  contact: {}
  geodata:
    latitude: 41.878
    formatted: Chicago, IL, USA
    longitude: -87.63
    original: Chicago, Illinois
- status: 
  contact_backup: {}
  facility:
    name: University of Rochester Medical Center
    address:
      city: Rochester
      state: New York
      zip: '14642'
      country: United States
  investigator: []
  contact: {}
  geodata:
    latitude: 43.161
    formatted: Rochester, NY, USA
    longitude: -77.611
    original: Rochester, New York
- status: 
  contact_backup: {}
  facility:
    name: University of Utah
    address:
      city: Salt Lake City
      state: Utah
      zip: 
      country: United States
  investigator: []
  contact: {}
  geodata:
    latitude: 40.761
    formatted: Salt Lake City, UT, USA
    longitude: -111.891
    original: Salt Lake City, Utah
official_title: A Multi-center Study to Evaluate the Pharmacokinetics of 21-Desacetyldeflazacort
  and the Safety of Deflazacort After Oral Administration of Deflazacort Tablets to
  Children and Adolescent Subjects With Duchenne Muscular Dystrophy
verification_date: September 2015
required_header:
  url: https://clinicaltrials.gov/show/NCT02251600
  link_text: Link to the current ClinicalTrials.gov record.
overall_contact: {}
brief_title: A Pharmacokinetic Study of Oral Deflazacort in Children and Adolescent
  Subjects With Duchenne Muscular Dystrophy
biospec_descr: {}
condition_browse:
  mesh_term:
  - Muscular Dystrophies
  - Muscular Dystrophy, Duchenne
brief_summary:
  textblock: |-
    Study to characterize the single-state and steady-state dosing of oral deflazacort in
          pediatric and adolescents subjects.
enrollment:
  attributes:
    type: Actual
  value: '24'
lastchanged_date: October 20, 2015
